| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 12 | 2024 | 366 | 1.620 |
Why?
|
| Spike Glycoprotein, Coronavirus | 13 | 2025 | 190 | 1.530 |
Why?
|
| Alanine Racemase | 11 | 2011 | 12 | 1.350 |
Why?
|
| Viral Vaccines | 7 | 2021 | 333 | 0.930 |
Why?
|
| Chagas Disease | 10 | 2024 | 294 | 0.910 |
Why?
|
| Recombinant Proteins | 17 | 2023 | 1390 | 0.880 |
Why?
|
| Lyme Disease | 4 | 2025 | 35 | 0.830 |
Why?
|
| Pandemics | 7 | 2022 | 1099 | 0.800 |
Why?
|
| Bacterial Proteins | 6 | 2025 | 889 | 0.720 |
Why?
|
| Vaccination | 10 | 2024 | 954 | 0.700 |
Why?
|
| Protozoan Vaccines | 6 | 2024 | 96 | 0.670 |
Why?
|
| Adjuvants, Immunologic | 8 | 2024 | 383 | 0.660 |
Why?
|
| Borrelia burgdorferi | 3 | 2025 | 19 | 0.650 |
Why?
|
| Vaccines, Synthetic | 8 | 2022 | 317 | 0.620 |
Why?
|
| Coronavirus Infections | 6 | 2021 | 358 | 0.600 |
Why?
|
| Transcription, Genetic | 1 | 2024 | 1697 | 0.600 |
Why?
|
| RNA, Messenger | 2 | 2024 | 2816 | 0.590 |
Why?
|
| Trypanosoma cruzi | 6 | 2021 | 236 | 0.530 |
Why?
|
| Saccharomycetales | 5 | 2021 | 37 | 0.500 |
Why?
|
| Neglected Diseases | 2 | 2015 | 151 | 0.490 |
Why?
|
| Pseudomonas aeruginosa | 4 | 2003 | 165 | 0.490 |
Why?
|
| Leishmaniasis Vaccines | 3 | 2020 | 20 | 0.470 |
Why?
|
| Universities | 1 | 2015 | 125 | 0.470 |
Why?
|
| Developing Countries | 2 | 2016 | 270 | 0.450 |
Why?
|
| Drug Discovery | 1 | 2015 | 171 | 0.450 |
Why?
|
| Animals | 37 | 2025 | 34081 | 0.430 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 3 | 2025 | 22 | 0.430 |
Why?
|
| Cost-Benefit Analysis | 4 | 2024 | 510 | 0.410 |
Why?
|
| Antibodies, Viral | 10 | 2024 | 1151 | 0.410 |
Why?
|
| Vaccines, Subunit | 2 | 2024 | 66 | 0.400 |
Why?
|
| Protozoan Proteins | 3 | 2018 | 111 | 0.400 |
Why?
|
| Ixodes | 2 | 2022 | 15 | 0.400 |
Why?
|
| Escherichia coli | 9 | 2024 | 985 | 0.400 |
Why?
|
| Gene Expression | 5 | 2021 | 1562 | 0.390 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 372 | 0.350 |
Why?
|
| Lyme Disease Vaccines | 3 | 2025 | 12 | 0.350 |
Why?
|
| Phlebotomus | 2 | 2020 | 17 | 0.340 |
Why?
|
| Antibodies, Neutralizing | 9 | 2024 | 468 | 0.330 |
Why?
|
| Antigens, Protozoan | 3 | 2024 | 66 | 0.320 |
Why?
|
| Genes, Bacterial | 3 | 2001 | 209 | 0.320 |
Why?
|
| Mice, Inbred BALB C | 9 | 2024 | 1004 | 0.320 |
Why?
|
| Serratia marcescens | 2 | 1999 | 10 | 0.310 |
Why?
|
| Immunoassay | 4 | 2022 | 130 | 0.310 |
Why?
|
| Streptococcus pneumoniae | 2 | 2011 | 375 | 0.310 |
Why?
|
| Saccharomyces cerevisiae | 5 | 2023 | 428 | 0.300 |
Why?
|
| Betacoronavirus | 3 | 2020 | 287 | 0.300 |
Why?
|
| Protein Domains | 7 | 2025 | 237 | 0.300 |
Why?
|
| DNA | 3 | 2024 | 1597 | 0.300 |
Why?
|
| Ascariasis | 2 | 2020 | 68 | 0.290 |
Why?
|
| Immunoglobulin G | 5 | 2022 | 777 | 0.290 |
Why?
|
| Aptamers, Nucleotide | 3 | 2013 | 28 | 0.280 |
Why?
|
| Nanoparticles | 3 | 2015 | 232 | 0.280 |
Why?
|
| Amino Acid Sequence | 11 | 2021 | 2705 | 0.280 |
Why?
|
| Cloning, Molecular | 7 | 2021 | 891 | 0.280 |
Why?
|
| Alum Compounds | 3 | 2022 | 41 | 0.280 |
Why?
|
| Immunoglobulin Fc Fragments | 2 | 2025 | 30 | 0.280 |
Why?
|
| Schistosomiasis | 3 | 2016 | 50 | 0.280 |
Why?
|
| Humans | 51 | 2025 | 124602 | 0.270 |
Why?
|
| Mice | 19 | 2025 | 17639 | 0.270 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2011 | 380 | 0.260 |
Why?
|
| Hookworm Infections | 3 | 2016 | 124 | 0.260 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2024 | 102 | 0.250 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2020 | 37 | 0.250 |
Why?
|
| Bacteriophage M13 | 2 | 2015 | 18 | 0.250 |
Why?
|
| Antibodies, Protozoan | 4 | 2018 | 76 | 0.250 |
Why?
|
| Leishmaniasis | 2 | 2016 | 33 | 0.250 |
Why?
|
| Aluminum Hydroxide | 2 | 2022 | 40 | 0.240 |
Why?
|
| Vaccination Coverage | 2 | 2022 | 34 | 0.240 |
Why?
|
| Biological Assay | 2 | 2015 | 103 | 0.230 |
Why?
|
| Molecular Sequence Data | 10 | 2013 | 3878 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 4 | 2012 | 1586 | 0.230 |
Why?
|
| Markov Chains | 1 | 2024 | 84 | 0.220 |
Why?
|
| RNA Caps | 1 | 2024 | 31 | 0.220 |
Why?
|
| Salivary Proteins and Peptides | 2 | 2020 | 19 | 0.220 |
Why?
|
| Immunoglobulin E | 2 | 2015 | 161 | 0.210 |
Why?
|
| Transduction, Genetic | 1 | 2024 | 290 | 0.210 |
Why?
|
| Bacteriophages | 2 | 2015 | 88 | 0.210 |
Why?
|
| Immunity, Innate | 2 | 2024 | 375 | 0.210 |
Why?
|
| Adaptive Immunity | 1 | 2024 | 90 | 0.210 |
Why?
|
| Insect Proteins | 2 | 2020 | 99 | 0.210 |
Why?
|
| Genetic Engineering | 2 | 2018 | 160 | 0.210 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2022 | 5 | 0.200 |
Why?
|
| Ascaris suum | 2 | 2020 | 29 | 0.200 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 1089 | 0.200 |
Why?
|
| Viruses | 2 | 2015 | 123 | 0.200 |
Why?
|
| Antigens, Helminth | 3 | 2020 | 190 | 0.200 |
Why?
|
| Models, Animal | 1 | 2024 | 460 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2025 | 767 | 0.190 |
Why?
|
| Helminth Proteins | 2 | 2020 | 101 | 0.190 |
Why?
|
| Mycobacterium smegmatis | 2 | 2014 | 6 | 0.190 |
Why?
|
| Trichuriasis | 1 | 2022 | 31 | 0.190 |
Why?
|
| Transfection | 1 | 2024 | 1062 | 0.190 |
Why?
|
| Zebrafish | 1 | 2024 | 384 | 0.190 |
Why?
|
| Mycobacterium avium | 1 | 2001 | 15 | 0.180 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 131 | 0.180 |
Why?
|
| Borrelia | 1 | 2022 | 68 | 0.180 |
Why?
|
| Acinetobacter Infections | 1 | 2021 | 26 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2014 | 409 | 0.180 |
Why?
|
| HIV-1 | 1 | 2024 | 465 | 0.180 |
Why?
|
| Acinetobacter baumannii | 1 | 2021 | 37 | 0.180 |
Why?
|
| Antibodies, Helminth | 2 | 2020 | 125 | 0.180 |
Why?
|
| Computer Simulation | 2 | 2021 | 646 | 0.180 |
Why?
|
| Leishmania | 1 | 2020 | 29 | 0.170 |
Why?
|
| RNA, Ribosomal, 5S | 2 | 2010 | 8 | 0.170 |
Why?
|
| Pichia | 2 | 2017 | 56 | 0.170 |
Why?
|
| Rhodococcus | 1 | 2020 | 1 | 0.170 |
Why?
|
| Intention | 1 | 2021 | 93 | 0.170 |
Why?
|
| Immunoglobulin M | 2 | 2018 | 212 | 0.170 |
Why?
|
| Sequence Alignment | 6 | 2017 | 622 | 0.170 |
Why?
|
| Computational Biology | 2 | 2022 | 811 | 0.170 |
Why?
|
| Pepsin A | 1 | 2019 | 12 | 0.170 |
Why?
|
| Aspartic Acid Proteases | 1 | 2019 | 9 | 0.170 |
Why?
|
| Health Resources | 1 | 2021 | 115 | 0.160 |
Why?
|
| Cysteine | 2 | 2017 | 136 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 2 | 2017 | 325 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 243 | 0.160 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 149 | 0.160 |
Why?
|
| Endodeoxyribonucleases | 1 | 1999 | 46 | 0.160 |
Why?
|
| Genome, Bacterial | 1 | 2020 | 187 | 0.160 |
Why?
|
| Antibodies, Catalytic | 1 | 2018 | 7 | 0.150 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 203 | 0.150 |
Why?
|
| Endoribonucleases | 1 | 1999 | 83 | 0.150 |
Why?
|
| Administration, Intranasal | 3 | 2024 | 134 | 0.150 |
Why?
|
| Biomedical Research | 4 | 2016 | 517 | 0.150 |
Why?
|
| Endonucleases | 1 | 1998 | 54 | 0.150 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 280 | 0.150 |
Why?
|
| Biotinylation | 2 | 2015 | 22 | 0.150 |
Why?
|
| Molecular Weight | 3 | 2020 | 390 | 0.140 |
Why?
|
| Superantigens | 1 | 2017 | 20 | 0.140 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2017 | 7 | 0.140 |
Why?
|
| Fluorometry | 1 | 2017 | 27 | 0.140 |
Why?
|
| Alanine | 2 | 2007 | 183 | 0.140 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 342 | 0.130 |
Why?
|
| Th2 Cells | 1 | 2017 | 185 | 0.130 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2014 | 395 | 0.130 |
Why?
|
| Phospholipids | 1 | 2017 | 105 | 0.130 |
Why?
|
| Temperature | 2 | 2017 | 303 | 0.130 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2016 | 14 | 0.130 |
Why?
|
| Crystallization | 3 | 2007 | 83 | 0.130 |
Why?
|
| Antigens, Viral | 1 | 2018 | 439 | 0.130 |
Why?
|
| Aptamers, Peptide | 1 | 2015 | 3 | 0.130 |
Why?
|
| Leishmania donovani | 1 | 2016 | 23 | 0.130 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2015 | 14 | 0.130 |
Why?
|
| Organizations, Nonprofit | 1 | 2015 | 20 | 0.120 |
Why?
|
| Drug Industry | 1 | 2015 | 46 | 0.120 |
Why?
|
| Mutant Proteins | 1 | 2016 | 115 | 0.120 |
Why?
|
| Crystallography, X-Ray | 5 | 2025 | 356 | 0.120 |
Why?
|
| Mass Spectrometry | 3 | 2012 | 330 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 142 | 0.120 |
Why?
|
| Magnetite Nanoparticles | 1 | 2015 | 9 | 0.120 |
Why?
|
| World Health Organization | 1 | 2015 | 101 | 0.120 |
Why?
|
| Helminthiasis | 1 | 2016 | 77 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 504 | 0.120 |
Why?
|
| Orotidine-5'-Phosphate Decarboxylase | 1 | 1994 | 3 | 0.120 |
Why?
|
| Biosensing Techniques | 2 | 2012 | 53 | 0.120 |
Why?
|
| Alkaline Phosphatase | 1 | 2015 | 97 | 0.120 |
Why?
|
| Ascorbic Acid | 1 | 2015 | 78 | 0.120 |
Why?
|
| Amino Acid Isomerases | 1 | 2014 | 7 | 0.120 |
Why?
|
| Malaria | 1 | 2015 | 85 | 0.120 |
Why?
|
| Models, Molecular | 5 | 2025 | 1069 | 0.120 |
Why?
|
| Goals | 1 | 2015 | 129 | 0.120 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2014 | 15 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 579 | 0.120 |
Why?
|
| Sensitivity and Specificity | 5 | 2022 | 2050 | 0.120 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2014 | 27 | 0.110 |
Why?
|
| Genes, Essential | 1 | 2014 | 40 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 492 | 0.110 |
Why?
|
| Gold | 1 | 2014 | 48 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 218 | 0.110 |
Why?
|
| RNA | 2 | 2024 | 570 | 0.110 |
Why?
|
| Dengue Virus | 2 | 2012 | 127 | 0.110 |
Why?
|
| Complement Factor H | 2 | 2025 | 21 | 0.110 |
Why?
|
| Levivirus | 1 | 2013 | 3 | 0.110 |
Why?
|
| Encephalitis Virus, Japanese | 1 | 2013 | 21 | 0.110 |
Why?
|
| Immunization | 3 | 2022 | 307 | 0.110 |
Why?
|
| Tropical Medicine | 1 | 2015 | 104 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1994 | 257 | 0.110 |
Why?
|
| Genetic Vectors | 3 | 2024 | 940 | 0.100 |
Why?
|
| Chemical Precipitation | 1 | 2012 | 15 | 0.100 |
Why?
|
| Technology | 2 | 2024 | 64 | 0.100 |
Why?
|
| beta-Globins | 1 | 2012 | 6 | 0.100 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2011 | 658 | 0.100 |
Why?
|
| Bacteriophage lambda | 1 | 2012 | 27 | 0.100 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2012 | 28 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 217 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 5 | 2021 | 759 | 0.100 |
Why?
|
| Peroxidase | 1 | 2012 | 62 | 0.100 |
Why?
|
| Oligonucleotides | 1 | 2012 | 89 | 0.100 |
Why?
|
| Fermentation | 3 | 2020 | 66 | 0.100 |
Why?
|
| Anemia | 1 | 2016 | 339 | 0.100 |
Why?
|
| Dimerization | 3 | 2007 | 144 | 0.100 |
Why?
|
| Cricetulus | 2 | 2025 | 100 | 0.100 |
Why?
|
| Poverty | 1 | 2015 | 422 | 0.100 |
Why?
|
| Caliciviridae Infections | 1 | 2015 | 328 | 0.100 |
Why?
|
| Deoxyribonucleases | 1 | 2011 | 27 | 0.100 |
Why?
|
| CHO Cells | 2 | 2025 | 160 | 0.100 |
Why?
|
| DNA, Bacterial | 2 | 2007 | 478 | 0.100 |
Why?
|
| Female | 14 | 2025 | 66491 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2025 | 432 | 0.090 |
Why?
|
| Nucleic Acids | 1 | 2011 | 23 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 1999 | 1533 | 0.090 |
Why?
|
| Norovirus | 1 | 2015 | 317 | 0.090 |
Why?
|
| DNA, Catalytic | 1 | 2010 | 3 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 96 | 0.090 |
Why?
|
| Protein Conformation | 3 | 2019 | 830 | 0.080 |
Why?
|
| Staining and Labeling | 3 | 2017 | 186 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2022 | 266 | 0.080 |
Why?
|
| Macaca mulatta | 2 | 2021 | 491 | 0.080 |
Why?
|
| Rosaniline Dyes | 1 | 2009 | 4 | 0.080 |
Why?
|
| Binding Sites | 4 | 2022 | 1295 | 0.080 |
Why?
|
| Antigens, Bacterial | 2 | 2025 | 314 | 0.080 |
Why?
|
| Bacillus anthracis | 1 | 2009 | 40 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 396 | 0.080 |
Why?
|
| Viral Load | 2 | 2021 | 384 | 0.080 |
Why?
|
| Protein Stability | 2 | 2020 | 162 | 0.080 |
Why?
|
| United States | 5 | 2024 | 10887 | 0.080 |
Why?
|
| Epitopes | 2 | 2022 | 432 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 264 | 0.080 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2020 | 48 | 0.070 |
Why?
|
| Base Sequence | 2 | 2007 | 3090 | 0.070 |
Why?
|
| Protein Binding | 3 | 2021 | 1738 | 0.070 |
Why?
|
| Genetic Complementation Test | 1 | 2007 | 88 | 0.070 |
Why?
|
| Gene Deletion | 3 | 2014 | 791 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2021 | 794 | 0.070 |
Why?
|
| Freeze Drying | 1 | 2024 | 15 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 533 | 0.060 |
Why?
|
| Fluorescent Dyes | 2 | 2017 | 261 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2024 | 195 | 0.060 |
Why?
|
| Proteins | 2 | 2023 | 1036 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2005 | 291 | 0.060 |
Why?
|
| Imines | 1 | 2003 | 9 | 0.060 |
Why?
|
| Neutralization Tests | 1 | 2024 | 237 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 122 | 0.050 |
Why?
|
| HIV Infections | 1 | 2015 | 1892 | 0.050 |
Why?
|
| Fluorescence | 2 | 2017 | 95 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 382 | 0.050 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2024 | 107 | 0.050 |
Why?
|
| Protein Multimerization | 2 | 2016 | 128 | 0.050 |
Why?
|
| Lung | 2 | 2021 | 1491 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 388 | 0.050 |
Why?
|
| Cycloserine | 1 | 2003 | 22 | 0.050 |
Why?
|
| Staphylococcal Protein A | 1 | 2022 | 7 | 0.050 |
Why?
|
| Nucleoproteins | 1 | 2022 | 25 | 0.050 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2003 | 33 | 0.050 |
Why?
|
| Antigens | 1 | 2023 | 155 | 0.050 |
Why?
|
| Mice, Inbred AKR | 1 | 2022 | 14 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 364 | 0.050 |
Why?
|
| Trichuris | 1 | 2022 | 26 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2024 | 744 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2022 | 88 | 0.050 |
Why?
|
| Masks | 1 | 2022 | 38 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 120 | 0.050 |
Why?
|
| Immunity, Mucosal | 1 | 2022 | 87 | 0.050 |
Why?
|
| Vibrio cholerae | 1 | 2021 | 26 | 0.050 |
Why?
|
| Rabbits | 1 | 2022 | 709 | 0.050 |
Why?
|
| Cholera | 1 | 2021 | 25 | 0.050 |
Why?
|
| Models, Economic | 1 | 2021 | 51 | 0.050 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2021 | 31 | 0.050 |
Why?
|
| Malaria, Falciparum | 1 | 2021 | 46 | 0.050 |
Why?
|
| Bacterial Vaccines | 1 | 2021 | 99 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 208 | 0.050 |
Why?
|
| Plasmodium falciparum | 1 | 2021 | 64 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2022 | 153 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2007 | 1758 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 205 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2021 | 125 | 0.040 |
Why?
|
| Antibodies | 1 | 2022 | 373 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 180 | 0.040 |
Why?
|
| Chickens | 2 | 2013 | 637 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 2 | 2011 | 98 | 0.040 |
Why?
|
| Disease Eradication | 1 | 2020 | 32 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2021 | 134 | 0.040 |
Why?
|
| DNA Primers | 1 | 2001 | 657 | 0.040 |
Why?
|
| Latin America | 1 | 2020 | 92 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2019 | 44 | 0.040 |
Why?
|
| Mexico | 1 | 2020 | 182 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2020 | 92 | 0.040 |
Why?
|
| Soil | 1 | 2020 | 55 | 0.040 |
Why?
|
| Eosinophils | 1 | 2020 | 120 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2020 | 147 | 0.040 |
Why?
|
| Operon | 1 | 1999 | 52 | 0.040 |
Why?
|
| Internet | 1 | 2022 | 375 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 1999 | 215 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 1018 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 172 | 0.040 |
Why?
|
| Nitriles | 1 | 2020 | 146 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2019 | 44 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2020 | 142 | 0.040 |
Why?
|
| Protein Folding | 1 | 2019 | 216 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 473 | 0.040 |
Why?
|
| Biotechnology | 1 | 1998 | 55 | 0.040 |
Why?
|
| Monocytes | 1 | 2020 | 352 | 0.040 |
Why?
|
| Freezing | 1 | 2017 | 28 | 0.040 |
Why?
|
| Plasmids | 1 | 1999 | 510 | 0.040 |
Why?
|
| Protein Precursors | 1 | 1998 | 153 | 0.040 |
Why?
|
| Phylogeny | 1 | 2020 | 695 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2017 | 54 | 0.040 |
Why?
|
| Cholera Toxin | 1 | 2017 | 50 | 0.040 |
Why?
|
| Industrial Microbiology | 1 | 2017 | 6 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2017 | 43 | 0.040 |
Why?
|
| Software | 1 | 2022 | 683 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 139 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2017 | 161 | 0.030 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 458 | 0.030 |
Why?
|
| Parasite Load | 1 | 2016 | 31 | 0.030 |
Why?
|
| Larva | 1 | 2017 | 245 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 84 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 173 | 0.030 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2016 | 11 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 5825 | 0.030 |
Why?
|
| Schistosoma mansoni | 1 | 2016 | 24 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2016 | 57 | 0.030 |
Why?
|
| Schistosoma haematobium | 1 | 2016 | 18 | 0.030 |
Why?
|
| Psychodidae | 1 | 2016 | 14 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2016 | 97 | 0.030 |
Why?
|
| Dynamic Light Scattering | 1 | 2016 | 9 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2750 | 0.030 |
Why?
|
| Tetraspanins | 1 | 2016 | 30 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 406 | 0.030 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2016 | 18 | 0.030 |
Why?
|
| Anthelmintics | 1 | 2016 | 55 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 357 | 0.030 |
Why?
|
| Primates | 1 | 2016 | 77 | 0.030 |
Why?
|
| Necator americanus | 1 | 2016 | 91 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 1291 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2016 | 153 | 0.030 |
Why?
|
| Holmium | 1 | 2015 | 9 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 2015 | 20 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2016 | 346 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 325 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 768 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1185 | 0.030 |
Why?
|
| Peptidoglycan | 1 | 2014 | 17 | 0.030 |
Why?
|
| Cell Wall | 1 | 2014 | 34 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2014 | 13 | 0.030 |
Why?
|
| Pyridoxal Phosphate | 2 | 2005 | 14 | 0.030 |
Why?
|
| Porosity | 1 | 2014 | 38 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 57 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2014 | 45 | 0.030 |
Why?
|
| Hydrogen Bonding | 2 | 2005 | 79 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 286 | 0.030 |
Why?
|
| Microfluidics | 1 | 2014 | 19 | 0.030 |
Why?
|
| Gadolinium | 1 | 2015 | 105 | 0.030 |
Why?
|
| Lectins | 1 | 2014 | 52 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 49 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2876 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 2426 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 502 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2014 | 74 | 0.030 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 42 | 0.030 |
Why?
|
| Nanostructures | 1 | 2014 | 51 | 0.030 |
Why?
|
| Culture Media | 1 | 2014 | 182 | 0.030 |
Why?
|
| Horseradish Peroxidase | 1 | 2013 | 14 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 381 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 172 | 0.030 |
Why?
|
| Light | 1 | 2014 | 176 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2014 | 203 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 48 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 822 | 0.030 |
Why?
|
| Muramidase | 1 | 2013 | 94 | 0.030 |
Why?
|
| Hemin | 1 | 2012 | 17 | 0.030 |
Why?
|
| G-Quadruplexes | 1 | 2012 | 10 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 2047 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2012 | 63 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1496 | 0.030 |
Why?
|
| Iron | 1 | 2015 | 267 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1709 | 0.020 |
Why?
|
| Male | 3 | 2024 | 61198 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 2015 | 349 | 0.020 |
Why?
|
| Anomura | 1 | 2011 | 2 | 0.020 |
Why?
|
| Chromatography | 1 | 2011 | 44 | 0.020 |
Why?
|
| Durapatite | 1 | 2011 | 17 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 2891 | 0.020 |
Why?
|
| Heart | 1 | 2016 | 708 | 0.020 |
Why?
|
| Cattle | 1 | 2013 | 565 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 866 | 0.020 |
Why?
|
| Alanine Dehydrogenase | 1 | 2011 | 1 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 77 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2014 | 514 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 3694 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 796 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2011 | 292 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2011 | 158 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 240 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9014 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 2005 | 779 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 480 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 147 | 0.020 |
Why?
|
| Structural Homology, Protein | 1 | 2009 | 26 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 806 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2009 | 12 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 1323 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2009 | 184 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 209 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7182 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 1328 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 19279 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 4352 | 0.020 |
Why?
|
| Electrons | 1 | 2005 | 24 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2005 | 86 | 0.010 |
Why?
|
| Infant | 1 | 2020 | 12468 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 26714 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12324 | 0.010 |
Why?
|
| Geobacillus stearothermophilus | 1 | 2003 | 2 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 29440 | 0.010 |
Why?
|
| Aged | 1 | 2022 | 19703 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 2003 | 41 | 0.010 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2003 | 30 | 0.010 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2003 | 43 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2498 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2003 | 575 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 6292 | 0.010 |
Why?
|